GAMMA Investing’s Design Therapeutics DSGN Stock Holding History

GAMMA Investing’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$26.8K	Buy	2,135 +685	+47%	+$9.47K	﹤0.01%	2767
2026 Q2	$21K	Sell	1,450 -22	-1%	-$274	﹤0.01%	2813
2026 Q1	$15.7K	Buy	1,472 +722	+96%	+$7.3K	﹤0.01%	2850
2025 Q4	$7.04K	Buy	750 +307	+69%	+$2.4K	﹤0.01%	3132
2025 Q3	$3.34K	Buy	+443	New	+$2.22K	﹤0.01%	3318
2025 Q2	–	Sell	-228	Closed	-$880	–	3809
2025 Q1	$880	Sell	228 -842	-79%	-$4.02K	﹤0.01%	3582
2024 Q4	$6.6K	Buy	1,070 +653	+157%	+$3.78K	﹤0.01%	2793
2024 Q3	$2.24K	Buy	+417	New	+$1.96K	﹤0.01%	3034

Other funds holding DSGN

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's DSGN Position: Q3 2026 in Review

GAMMA Investing increased its Design Therapeutics (DSGN) stake by 47% in Q3 2026, buying an estimated $9.47K and bringing the position to 2,135 shares worth $26.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2767.

GAMMA Investing first reported a position in DSGN in Q3 2024 and has held it in 8 quarters since. 3 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

GAMMA Investing held 2,135 shares of Design Therapeutics worth $26.8K as of Q3 2026.
GAMMA Investing bought 685 Design Therapeutics shares in Q3 2026, an estimated $9.47K.
Design Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2767 holding.
GAMMA Investing first reported a position in Design Therapeutics in Q3 2024 and has held it in 8 quarters since.
3 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.